As the field of BCMA-directed bispecific antibodies in multiple myeloma grows more crowded, the question of how to position them on the market is becoming one of not only the traditional safety-efficacy profile, but also convenience. On that basis, Regeneron Pharmaceuticals, Inc. hopes to differentiate its candidate linvoseltamab from other players on the market and in development.
Meanwhile, Pfizer Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?